United Therapeutics Corporation (NASDAQ:UTHR) Director Nilda Mesa Sells 645 Shares

United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) Director Nilda Mesa sold 645 shares of United Therapeutics stock in a transaction dated Tuesday, June 24th. The stock was sold at an average price of $289.99, for a total value of $187,043.55. Following the sale, the director now owns 4,883 shares of the company's stock, valued at approximately $1,416,021.17. This represents a 11.67% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

United Therapeutics Stock Down 0.7%

Shares of United Therapeutics stock traded down $1.88 during trading hours on Thursday, hitting $284.09. 364,679 shares of the company's stock traded hands, compared to its average volume of 448,643. United Therapeutics Corporation has a twelve month low of $266.98 and a twelve month high of $417.82. The company has a market cap of $12.82 billion, a PE ratio of 11.34, a PEG ratio of 6.35 and a beta of 0.57. The stock has a 50 day simple moving average of $301.15 and a 200-day simple moving average of $326.23.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last posted its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.29 by $0.34. United Therapeutics had a return on equity of 19.33% and a net margin of 40.44%. The company had revenue of $794.40 million for the quarter, compared to the consensus estimate of $726.82 million. During the same period in the previous year, the business earned $6.17 EPS. United Therapeutics's revenue for the quarter was up 17.2% compared to the same quarter last year. As a group, equities research analysts predict that United Therapeutics Corporation will post 24.48 EPS for the current year.

Institutional Trading of United Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Dunhill Financial LLC increased its position in shares of United Therapeutics by 100.0% in the 4th quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company's stock worth $35,000 after purchasing an additional 50 shares during the last quarter. SVB Wealth LLC acquired a new position in United Therapeutics in the first quarter worth about $32,000. Geneos Wealth Management Inc. increased its holdings in United Therapeutics by 141.7% in the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company's stock valued at $45,000 after buying an additional 85 shares during the last quarter. Sound Income Strategies LLC bought a new stake in United Therapeutics in the first quarter valued at about $49,000. Finally, State of Wyoming acquired a new stake in United Therapeutics during the fourth quarter valued at approximately $62,000. 94.08% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on UTHR shares. Morgan Stanley raised their target price on shares of United Therapeutics from $346.00 to $348.00 and gave the stock an "equal weight" rating in a research report on Thursday, May 1st. Bank of America decreased their price target on United Therapeutics from $321.00 to $315.00 and set a "neutral" rating on the stock in a research note on Wednesday, June 11th. Cantor Fitzgerald assumed coverage on shares of United Therapeutics in a research report on Monday, June 2nd. They issued an "overweight" rating and a $405.00 target price on the stock. HC Wainwright reaffirmed a "buy" rating and set a $425.00 price target on shares of United Therapeutics in a research report on Monday, May 5th. Finally, JPMorgan Chase & Co. decreased their price target on shares of United Therapeutics from $355.00 to $350.00 and set an "overweight" rating on the stock in a report on Thursday, May 1st. Four equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to MarketBeat, United Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $393.08.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.